Dosing reference
Every dose that has been studied in humans
Label dosing for approved drugs, the amounts given in registered trials of investigational drugs, and a plain “none established” everywhere else. No forum numbers, no vendor charts. Every figure cites its source.
22 · FDA label15 · Trial doses71 · None established
Reconstitution guide
Lab steps with photos, syringe units and storage.
How long studies ran
Cycle-length evidence: treatment and follow-up durations.
Combinations
What is actually studied when compounds are paired.
Human dosing quick-reference chart
Click any compound for the cited dosing page, study durations and vial arithmetic.
| Compound | Research area | Status | Human amounts | Route studied | Half-life | Evidence | |
|---|---|---|---|---|---|---|---|
| 5-Amino-1MQ | Metabolic | Not approved | None established | — | — | C | View |
| Adipotide | Metabolic | Not approved | None established | — | Not located in the sources reviewed; no pharmacokinetic half-life for any species was reported in the sources used for this entry. | C | View |
| Amycretin | Metabolic | Investigational | Subcutaneous: 0.3 mg escalated up to 1.25–60 mg once weekly (phase 1b/2a); 0.2 mg start to maintenance 0.4–40 mg once weekly (phase 2, T2D). Oral: 1.5 mg start to 6, 25 or 50 mg once daily (phase 2, T2D); up to 2 × 50 mg daily in phase 1 | Subcutaneous injection or oral tablet | Geometric mean terminal half-life of 88.1 hours after a single 0.3 mg subcutaneous dose in participants with normal renal function (94.0–112.8 hours with renal impairment) | A | View |
| AOD-9604 | Metabolic | Not approved | None established | Oral in the obesity trial programme; intravenous in early single-administration studies, as summarised by a 2026 review | — | C | View |
| Cagrilintide | Metabolic | Investigational | Trial doses: 0.3 to 4.5 mg once weekly (phase 2 monotherapy); 2.4 mg once weekly in phase 3 (alone or with semaglutide 2.4 mg) | Subcutaneous injection | 159 to 195 hours (phase 1b, co-administered with semaglutide 2.4 mg) | A | View |
| Dulaglutide | Metabolic | FDA-approved | Adults: 0.75 mg once weekly to start; may increase to 1.5 mg after 4 weeks, then in 1.5 mg steps after at least 4 weeks; maximum 4.5 mg once weekly. Pediatric (10 years and older): 0.75 mg, maximum 1.5 mg once weekly | Subcutaneous injection | Approximately 5 days | A | View |
| Ecnoglutide | Metabolic | Approved outside the US | Not quoted: approved in China only, and the Chinese national register document was not opened for this entry | Subcutaneous injection in the trials reviewed; an oral tablet formulation is in development | 124 to 138 hours at steady state in healthy participants | A | View |
| Eloralintide | Metabolic | Investigational | Phase 1: single doses 0.04–12 mg; 12-week MAD 1.2–12 mg once weekly; phase 2: 1–9 mg once weekly for 48 weeks (fixed doses or 3→9 / 6→9 mg escalation) | Subcutaneous injection | Terminal geometric mean half-life of 310–366 hours (12.9–15.3 days) across single doses of 0.4–12 mg in healthy participants; median tmax 72–132 hours | A | View |
| Exenatide | Metabolic | FDA-approved | 5 micrograms twice daily to start; may increase to 10 micrograms twice daily after 1 month based on clinical response | Subcutaneous injection | Mean terminal half-life 2.4 hours | A | View |
| HGH Fragment 176-191 | Metabolic | Not approved | None established | — | — | C | View |
| Liraglutide | Metabolic | FDA-approved | Victoza: 0.6 mg → 1.2 mg, maximum 1.8 mg once daily (type 2 diabetes). Saxenda: 0.6 mg escalated weekly to 3 mg once daily (weight management; pediatric maintenance may be reduced to 2.4 mg) | Subcutaneous injection | Approximately 13 hours after subcutaneous administration | A | View |
| MariTide (maridebart cafraglutide) | Metabolic | Investigational | Trial amounts only: 140, 280 or 420 mg subcutaneously every 4 weeks, and 420 mg every 8 weeks, in the phase 2 dose-ranging trial NCT05669599 | Subcutaneous injection | Not reported numerically in the sources reviewed; the conjugate is described as giving markedly prolonged exposure of the intact GLP-1 peptide | A | View |
| Mazdutide | Metabolic | Approved outside the US | Trial doses: 3 to 6 mg once weekly (most phase 3 trials), 9 mg in GLORY-2, up to 16 mg in a US phase 2 trial | Subcutaneous injection | 150.9 to 403.5 hours (phase 1b in overweight/obesity) | A | View |
| MOTS-c | Metabolic | Not approved | None established | — | — | C | View |
| Orforglipron | Metabolic | FDA-approved | 0.8 mg once daily to start, escalated stepwise (2.5, 5.5, then optionally 9, 14.5, 17.2 mg) after at least 30 days per step; maximum 17.2 mg once daily (FOUNDAYO label) | Oral tablet | Approximately 29-49 hours | A | View |
| Pemvidutide | Metabolic | Investigational | 1.2, 1.8 or 2.4 mg once weekly without titration (phase 1 MASLD, 12–24 weeks); 1.2 or 1.8 mg (IMPACT phase 2b); phase 3 PERFORMA registered at 1.8 and 2.4 mg | Subcutaneous injection | A numerical human half-life was not located in the sources reviewed | A | View |
| Pramlintide | Metabolic | Approved, no longer marketed | Type 2 diabetes: 60 micrograms before each major meal, increased to 120 micrograms. Type 1 diabetes: 15 micrograms before each major meal, increased in 15-microgram steps to 30, 45 or 60 micrograms. Mealtime insulin reduced by 50% at initiation | Subcutaneous injection | Approximately 48 minutes | A | View |
| Retatrutide | Metabolic | Investigational | Phase 2: 0.5–12 mg once weekly (36–48 weeks); phase 3 (TRIUMPH-1, TRIUMPH-2, TRANSCEND-T2D-1): 4, 9 or 12 mg once weekly | Subcutaneous injection | Approximately 6 days (phase 1b multiple-ascending-dose study in type 2 diabetes) | A | View |
| Semaglutide | Metabolic | FDA-approved | Injection: 0.25 mg → 0.5, 1 or 2 mg once weekly (Ozempic); 0.25 mg → 1.7 or 2.4 mg once weekly, adult weight-reduction maximum 7.2 mg (Wegovy). Tablets: 3 mg → 7 or 14 mg once daily (Rybelsus); 1.5 mg → 4 or 9 mg once daily (Ozempic tablets); 1.5 mg → 25 mg once daily (Wegovy tablets) | Subcutaneous injection or oral tablet | Approximately 1 week; present in the circulation for about 5 weeks after the last dose (Ozempic label), about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection or 25 mg tablet (Wegovy label) | A | View |
| Setmelanotide | Metabolic | FDA-approved | Maintenance 3 mg once daily for patients aged 6 and older (all indications), after a 2-week starting dosage of 0.5 mg (acquired HO) or 2 mg (BBS/POMC/PCSK1/LEPR, age 12+); weight-based maintenance under age 6 (IMCIVREE label) | Subcutaneous injection | About 11 hours | A | View |
| SLU-PP-332 | Metabolic | Not approved | None established | — | Unknown in humans | C | View |
| Survodutide | Metabolic | Investigational | Phase 2: 0.6–6.0 mg once weekly (46–48 weeks); phase 3 SYNCHRONIZE: 3.6 mg or 6.0 mg once weekly (3.6 or 4.8 mg in SYNCHRONIZE-CN) | Subcutaneous injection | A numerical human half-life was not located in the abstracts reviewed | A | View |
| Tesofensine | Metabolic | Investigational | Trial doses: 0.125 to 1.0 mg once daily (phase 2); 0.5 mg in Tesomet combinations | Oral | About 234 hours (M1 metabolite about 374 hours), population PK in Alzheimer patients | B | View |
| Tirzepatide | Metabolic | FDA-approved | 2.5 mg once weekly start, increased in 2.5 mg steps every ≥4 weeks; Mounjaro maximum 15 mg (adults) or 10 mg (pediatric ≥10 years); Zepbound maintenance 5, 10 or 15 mg (OSA 10 or 15 mg), maximum 15 mg | Subcutaneous injection | Approximately 5 days (Mounjaro label); approximately 5 to 6 days in patients with overweight or obesity and in patients with OSA and obesity (Zepbound label) | A | View |
| VK2735 | Metabolic | Investigational | Phase 2 VENTURE: 2.5, 5.0, 10 or 15 mg once weekly for 13 weeks (titrated); phase 3 VANQUISH registered at 7.5, 12.5 and 17.5 mg once weekly; oral formulation tested once daily (amounts not in registry) | Subcutaneous injection; oral tablet in separate trials | A numerical half-life was not located; the VENTURE report states only that a side chain extends half-life after subcutaneous injection | A | View |
“Human amounts” is a summary; the dosing page for each compound carries the full cited statements. Compounds approved nowhere show “None established” by policy, whatever is circulated elsewhere. Why.
What every dosing page includes
- Quick-reference card
- Label or trial doses, cited
- How long studies ran
- Who was excluded
- Side effects reported
- Reconstitution arithmetic + syringe chart
- Supplies, storage and handling mistakes
- Regulatory status
- Comparison with related compounds
- Combinations and FAQs
Don’t see a compound?
Tell us what to research next. We add compounds when there are primary sources to cite.